Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Tianbao Lu, Richard Alexander, Gilles Bignan, James Bischoff, Peter Connolly, Max Cummings, Sabine De Breucker, Norbert Esser, Erwin Fraiponts, Ron Gilissen, Bruce Grasberger, Boudewijn Janssens, Donald Ludovici, Lieven Meerpoel | ||||||||||||
Title | Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/74/19_Supplement/4747 | ||||||||||||
Abstract Text | Cancer Res October 1, 2014 74; 4747 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
JNJ-54302833 | JNJ-54302833 | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-54302833 | SB19615 | FASN Inhibitor 5 | JNJ-54302833 is a fatty acid synthase (FASN) inhibitor that suppresses tumor cell growth in culture (PMID: 26519059). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|